» Articles » PMID: 28297009

Development and Validation of a Prognostic Score for Intrahepatic Cholangiocarcinoma

Overview
Journal JAMA Surg
Specialty General Surgery
Date 2017 Mar 16
PMID 28297009
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: In patients with intrahepatic cholangiocarcinoma (ICC), the oncologic benefit of surgery and perioperative outcomes for large multifocal tumors or tumors with contiguous organ involvement remain to be defined.

Objectives: To develop and externally validate a simplified prognostic score for ICC and to determine perioperative outcomes for large multifocal ICCs or tumors with contiguous organ involvement.

Design, Setting, And Participants: This study of a contemporary cohort merged data from the California Cancer Registry (January 1, 2004, through December 31, 2011) and the Office of Statewide Health Planning and Development inpatient database. Clinicopathologic variables were compared between tumors that were intrahepatic, small (<7 cm), and solitary (ISS) and those that had extrahepatic extension and were large (≥7 cm) and multifocal (ELM). External validation of the prognostic model was performed using an independent data set from the National Cancer Institute's Surveillance, Epidemiology, and End Results database from January 1, 2004, through December 31, 2013.

Main Outcomes And Measures: Patient overall survival after hepatectomy.

Results: A total of 275 patients (123 men [44.7%] and 152 women [55.3%]; median [interquartile range] age, 65 [55-72] years) met the inclusion criteria. No significant differences in overall complication rate (ISS, 48 [34.5%]; ELM, 37 [27.2%]; P = .19) and mortality rate (ISS, 10 [7.2%]; ELM, 6 [4.4%]; P = .32) were found. A multivariate Cox proportional hazards model demonstrated that multifocality, extrahepatic extension, grade, node positivity, and age greater than 60 years are independently associated with worse overall survival. These variables were used to develop the MEGNA prognostic score. The prognostic separation/discrimination index was improved with the MEGNA prognostic score (0.21; 95% CI, 0.11-0.33) compared with the staging systems of the American Joint Committee on Cancer sixth (0.17; 95% CI, 0.09-0.29) and seventh (0.18; 95% CI, 0.08-0.30) editions.

Conclusions And Relevance: The MEGNA prognostic score allows more accurate and superior estimation of patient survival after hepatectomy compared with current staging systems.

Citing Articles

Introducing and Validating the Multiphasic Evidential Decision-Making Matrix (MedMax) for Clinical Management in Patients with Intrahepatic Cholangiocarcinoma.

Ramouz A, Adeliansedehi A, Khajeh E, Marz K, Michael D, Wagner M Cancers (Basel). 2025; 17(1.

PMID: 39796681 PMC: 11718823. DOI: 10.3390/cancers17010052.


Has Management of Intrahepatic Cholangiocarcinoma Evolved with the Evidence? Trends and Practice Patterns from the National Cancer Database.

Schleimer L, Kalvin H, Ellis R, Kingham T, Soares K, DAngelica M Ann Surg Oncol. 2024; 31(10):6551-6563.

PMID: 39042229 DOI: 10.1245/s10434-024-15724-9.


A personalized prognostic model for long-term survival in patients with intrahepatic cholangiocarcinoma: a retrospective cohort study.

Dong X, Zhang P, Ye C, Li L Ann Surg Treat Res. 2024; 107(1):16-26.

PMID: 38978684 PMC: 11227918. DOI: 10.4174/astr.2024.107.1.16.


Application of AI on cholangiocarcinoma.

Huang J, Bai X, Qiu Y, He X Front Oncol. 2024; 14:1324222.

PMID: 38347839 PMC: 10859478. DOI: 10.3389/fonc.2024.1324222.


Call to Improve the Quality of Prediction Tools for Intrahepatic Cholangiocarcinoma Resection: A Critical Appraisal, Systematic Review, and External Validation Study.

Choi W, Walker R, Rajendran L, Jones O, Gravely A, Englesakis M Ann Surg Open. 2023; 4(3):e328.

PMID: 37746604 PMC: 10513309. DOI: 10.1097/AS9.0000000000000328.


References
1.
Yamamoto M, Takasaki K, Yoshikawa T . Extended resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg. 1999; 6(2):117-21. DOI: 10.1007/s005340050093. View

2.
Brandi G, Farioli A, Astolfi A, Biasco G, Tavolari S . Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget. 2015; 6(17):14744-53. PMC: 4558112. DOI: 10.18632/oncotarget.4539. View

3.
Chang K, Chang J, Yen Y . Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J Natl Compr Canc Netw. 2009; 7(4):423-7. DOI: 10.6004/jnccn.2009.0030. View

4.
Weber S, Ribero D, OReilly E, Kokudo N, Miyazaki M, Pawlik T . Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015; 17(8):669-80. PMC: 4527852. DOI: 10.1111/hpb.12441. View

5.
Doussot A, Groot-Koerkamp B, Wiggers J, Chou J, Gonen M, DeMatteo R . Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models. J Am Coll Surg. 2015; 221(2):452-61. PMC: 4784264. DOI: 10.1016/j.jamcollsurg.2015.04.009. View